Nimbus Therapeutics, LLC, a biotechnology company that designs and develops medicines leveraging its computational drug discovery engine, has achieved a significant preclinical milestone under its collaboration with Lilly, targeting a specific isoform of AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases. AMPK, a key regulator of cellular energy metabolism, is a recognized promising therapeutic target. Despite its potential, developing selective activators of sp...